Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 218

Results For "CE"

8540 News Found

Stelis Biopharma’s flagship facility receives EIR from USFDA
Drug Approval | January 19, 2023

Stelis Biopharma’s flagship facility receives EIR from USFDA

The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes


Panacea Biotec donates 125,000 doses of Easyfive-TT to Cuba
News | January 18, 2023

Panacea Biotec donates 125,000 doses of Easyfive-TT to Cuba

This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba


1st G20 Health Working Group Meeting to commence on 18th January at Thiruvananthapuram
Policy | January 17, 2023

1st G20 Health Working Group Meeting to commence on 18th January at Thiruvananthapuram

India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health


USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions
Drug Approval | January 17, 2023

USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions

The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22


Lonza completes expansion to Solid Form Services Facility at Bend (US) site
News | January 17, 2023

Lonza completes expansion to Solid Form Services Facility at Bend (US) site

New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement


Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets
Drug Approval | January 17, 2023

Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets

Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)


TSCS organizes training program for prevention and eradication of thalassemia & sickle cell
News | January 16, 2023

TSCS organizes training program for prevention and eradication of thalassemia & sickle cell

A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project


Zydus receives tentative approval from USFDA for Levomilnacipran Extended-Release Capsules
Drug Approval | January 16, 2023

Zydus receives tentative approval from USFDA for Levomilnacipran Extended-Release Capsules

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India


Dr. Reddy’s acquires trademark rights of breast cancer drug PRIMCYV from Pfizer
News | January 14, 2023

Dr. Reddy’s acquires trademark rights of breast cancer drug PRIMCYV from Pfizer

Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA


Mastek partners King Faisal Specialist Hospital & Research Centre for healthcare transformation
News | January 13, 2023

Mastek partners King Faisal Specialist Hospital & Research Centre for healthcare transformation

The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client